AVITA Medical, Inc. (RCEL) Stock

AVITA Medical, Inc. operates as a prominent regenerative tissue company with a commercial presence spanning the United States, Australia, and the United Kingdom. Specializing in addressing critical medical needs, the company offers advanced regenerative products designed for burn injuries, trauma injuries, chronic wounds, and various dermatological and aesthetic indications, including vitiligo. Central to AVITA's approach is its patented platform technology, which harnesses the regenerative properties of a patient's own skin to develop innovative treatment solutions.

The cornerstone of AVITA Medical, Inc.'s product portfolio is the RECELL System, a pioneering device that empowers healthcare professionals to create a suspension of Spray-On Skin cells using a small sample of the patient's own skin. This innovative approach facilitates the treatment of acute thermal burns in adult patients, providing a significant advancement in burn care management.

Founded in 2000 and headquartered in Valencia, California, AVITA Medical, Inc. has established strategic research collaborations to further enhance its technological capabilities. These include partnerships with the University of Colorado School of Medicine, focusing on pre-clinical proof-of-concept for a spray-on treatment using genetically corrected cells, and with the Houston Methodist Research Institute, exploring molecular reversal of cellular aging through novel cell suspension delivery systems.

Formerly known as AVITA Therapeutics, Inc., the company rebranded as AVITA Medical, Inc. in December 2020 to better reflect its expanding focus and vision in regenerative medicine. With a commitment to innovation and patient-centric care, AVITA Medical continues to pioneer advancements that improve clinical outcomes and quality of life for patients worldwide.